-
Mashup Score: 0HRAS-Mutant HNSCC Delineated in 4 Data Sets - 1 year(s) ago
An analysis of 4 deidentified data sets revealed that HRAS mutations occurred in 3% to 4% of patients with head and neck squamous cell carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Ficlatuzumab plus cetuximab has demonstrated antitumor activity in pan-refractory, recurrent/metastatic head and neck squamous cell carcinoma.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of ficlatuzumab and cetuximab has demonstrated antitumor activity in patients with pan-refractory, recurrent or metastatic head and neck squamous cell carcinoma. Published in the @JCO_ASCO. https://t.co/sOCfFSDlIJ #HNSCC #HeadandNeckCancer
-
-
Mashup Score: 0
Findings from a phase 2/3 trial found better disease-free and overall survival outcomes with radiation plus docetaxel vs radiation alone in head and neck squamous cell carcinoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding Docetaxel to Radiation Boosts Survival in Cisplatin-Ineligible HNSCC #oncology #nursing #radiation #HNSCC @TataMemorial https://t.co/eep0hchGpk
-
-
Mashup Score: 0Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCC - 1 year(s) ago
Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCC #immunotherapy #chemotherapy #HNSCC #oncology #nursing https://t.co/asoTUT8DlW
-
-
Mashup Score: 0
Findings from a phase 2/3 trial found better disease-free and overall survival outcomes with radiation plus docetaxel vs radiation alone in head and neck squamous cell carcinoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding Docetaxel to Radiation Boosts Survival in Cisplatin-Ineligible HNSCC #oncology #nursing #radiation #HNSCC @TataMemorial https://t.co/0TVBshnmsQ
-
-
Mashup Score: 1
Radiation plus docetaxel improved disease-free survival and overall survival vs radiation alone in patients with head and neck squamous cell carcinoma unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups, according to findings from a phase 2/3 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to a phase 2/3 trial, radiation + docetaxel improved DFS and OS vs radiation alone in patients w/ HNSCC unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups. @DrVijayPatil11 @JCO_ASCO #hnscc https://t.co/LdrPDq7PpO https://t.co/qDfkd1IE4J
-
-
Mashup Score: 0
Radiation plus docetaxel improved disease-free survival and overall survival vs radiation alone in patients with head and neck squamous cell carcinoma unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups, according to findings from a phase 2/3 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Radiation + docetaxel improved DFS and OS vs radiation alone in patients w/ head and neck squamous cell carcinoma unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups. @DrVijayPatil11 @JCO_ASCO #hnscc https://t.co/sJQnAR3VNk
-
-
Mashup Score: 0
Radiation plus docetaxel improved disease-free survival and overall survival vs radiation alone in patients with head and neck squamous cell carcinoma unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups, according to findings from a phase 2/3 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC @DrVijayPatil11 @TataMemorial @JCO_ASCO #hnscc https://t.co/SZGl7XxDBZ
-
-
Mashup Score: 0Checkmate 651 Misses Primary End Points With Frontline Nivolumab/Ipilimumab in Recurrent/Metastatic HNSCC - 1 year(s) ago
There continues to be an unmet need for effective and tolerable frontline treatments for patients with squamous cell carcinoma of the head and neck, according to investigators.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Checkmate 651 Misses Primary End Points With Frontline Nivolumab/Ipilimumab in Recurrent/Metastatic HNSCC #immunotherapy #HNSCC #oncology #nursing Link: https://t.co/GYbWq7qNH1 https://t.co/lNPDWd1V40
-
-
Mashup Score: 0Proton Therapy Reirradiation for Patients With Recurrent HNSCC - 1 year(s) ago
This cohort study of patients with head and neck squamous cell carcinoma examines the outcomes and toxic effects associated with proton therapy reirradiation for patients with head and neck squamous cell carcinoma.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Patients with recurrent head & neck cancer receiving proton therapy have improved survival compared to historical controls, but the toxic effects may be substantial. #HNSCC https://t.co/ePpSfa56KC
-
An analysis of 4 deidentified data sets revealed that HRAS mutations occurred in 3% to 4% of patients with #HNSCC, with G12S being the most common, appearing in 29% of all point mutations. https://t.co/4agU0HRglE